AU2007353773A1 - Plant-made West Nile virus (WNV) vaccines, vectors and plant codon optimized sequences - Google Patents

Plant-made West Nile virus (WNV) vaccines, vectors and plant codon optimized sequences Download PDF

Info

Publication number
AU2007353773A1
AU2007353773A1 AU2007353773A AU2007353773A AU2007353773A1 AU 2007353773 A1 AU2007353773 A1 AU 2007353773A1 AU 2007353773 A AU2007353773 A AU 2007353773A AU 2007353773 A AU2007353773 A AU 2007353773A AU 2007353773 A1 AU2007353773 A1 AU 2007353773A1
Authority
AU
Australia
Prior art keywords
seq
polypeptide
fragment
set forth
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007353773A
Other languages
English (en)
Inventor
Steven L. Evans
Geoffrey J. Letchworth
Donald J. Merlo
Charles A. Mihaliak
Kelley A. Smith
Steven Robert Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Agriculture
Corteva Agriscience LLC
Original Assignee
Dow AgroSciences LLC
United States Department of Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow AgroSciences LLC, United States Department of Agriculture filed Critical Dow AgroSciences LLC
Publication of AU2007353773A1 publication Critical patent/AU2007353773A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2007353773A 2006-12-22 2007-12-21 Plant-made West Nile virus (WNV) vaccines, vectors and plant codon optimized sequences Abandoned AU2007353773A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87151806P 2006-12-22 2006-12-22
US60/871,518 2006-12-22
PCT/US2007/088512 WO2008143713A2 (en) 2006-12-22 2007-12-21 Plant-made west nile virus (wnv) vaccines, vectors and plant codon optimized sequences

Publications (1)

Publication Number Publication Date
AU2007353773A1 true AU2007353773A1 (en) 2008-11-27

Family

ID=40032322

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007353773A Abandoned AU2007353773A1 (en) 2006-12-22 2007-12-21 Plant-made West Nile virus (WNV) vaccines, vectors and plant codon optimized sequences

Country Status (8)

Country Link
US (1) US7888069B2 (enExample)
EP (1) EP2099916A2 (enExample)
JP (1) JP2010514698A (enExample)
AR (1) AR064500A1 (enExample)
AU (1) AU2007353773A1 (enExample)
BR (1) BRPI0721141A2 (enExample)
CA (1) CA2671934A1 (enExample)
WO (1) WO2008143713A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2439264B1 (en) * 2010-10-11 2015-06-03 Jennewein Biotechnologie GmbH Novel fucosyltransferases and their applications
WO2012095874A1 (en) 2011-01-11 2012-07-19 Enneffe S.R.L. Adjustable anti -theft device
WO2013191997A1 (en) * 2012-06-18 2013-12-27 Dow Agrosciences Llc Expression of maize codon optimized proteins in pseudomonas fluorescens
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine
US12443985B2 (en) 2022-12-16 2025-10-14 Sap Se Solving sparse data problems in a recommendation system with cold start
US12430678B2 (en) * 2022-12-16 2025-09-30 Sap Se Solving sparse data problems in a recommendation system with freezing start

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5428147A (en) * 1983-04-15 1995-06-27 Mycogen Plant Science, Inc. Octopine T-DNA promoters
US5380831A (en) * 1986-04-04 1995-01-10 Mycogen Plant Science, Inc. Synthetic insecticidal crystal protein gene
US5276268A (en) * 1986-08-23 1994-01-04 Hoechst Aktiengesellschaft Phosphinothricin-resistance gene, and its use
US5273894A (en) * 1986-08-23 1993-12-28 Hoechst Aktiengesellschaft Phosphinothricin-resistance gene, and its use
US5637489A (en) * 1986-08-23 1997-06-10 Hoechst Aktiengesellschaft Phosphinothricin-resistance gene, and its use
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DE3924454A1 (de) * 1989-07-24 1991-02-07 Cornelis P Prof Dr Hollenberg Die anwendung von dna und dna-technologie fuer die konstruktion von netzwerken zur verwendung in der chip-konstruktion und chip-produktion (dna chips)
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
CA2071943C (en) 1989-12-22 2007-04-24 Joan Tellefsen Odell Site-specific recombination of dna in plant cells
US5183740A (en) * 1990-02-23 1993-02-02 The United States Of America As Represented By The Secretary Of The Navy Flow immunosensor method and apparatus
US5384253A (en) * 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
TW261517B (enExample) * 1991-11-29 1995-11-01 Mitsubishi Shozi Kk
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
ES2176208T3 (es) 1992-10-05 2002-12-01 Univ North Carolina State Metodo para incrementar la expresion y para reducir la variabilidad de expresion de genes foraneos en celulas vegetales.
US6239328B1 (en) * 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
FI92882C (fi) * 1992-12-29 1995-01-10 Medix Biochemica Ab Oy Kertakäyttöinen testiliuska ja menetelmä sen valmistamiseksi
US5753439A (en) * 1995-05-19 1998-05-19 Trustees Of Boston University Nucleic acid detection methods
US5843464A (en) * 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5750352A (en) * 1995-08-23 1998-05-12 The Johns Hopkins University Mono-allelic mutation analysis for identifying germline mutations
US5773695A (en) * 1996-01-26 1998-06-30 North Carolina State University Plant nuclear scaffold attachment region and method for increasing gene expression in transgenic cells
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU7469998A (en) 1997-05-01 1998-11-24 Amgen, Inc. Chimeric opg polypeptides
US6214545B1 (en) * 1997-05-05 2001-04-10 Third Wave Technologies, Inc Polymorphism analysis by nucleic acid structure probing
HUP0003601A3 (en) * 1997-08-05 2003-03-28 Stressgen Biotechnologies Corp Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins
US6319691B1 (en) * 1999-06-15 2001-11-20 Usa Universe Bioengineering, Inc. Fusion proteins comprising IFN-alpha2b and TM-alpha1
US6342362B1 (en) * 1999-08-05 2002-01-29 Daniel S. Mytelka Methods and compositions for the purification of proteins or other macromolecules
KR101150584B1 (ko) * 2002-11-15 2012-06-27 사노피 파스테르 바이오로직스 씨오 웨스트 나일 바이러스 백신
KR20060029214A (ko) * 2003-05-05 2006-04-05 다우 아그로사이언시즈 엘엘씨 이식 유전자 식물 세포들로부터 유래된 안정한 면역예방적및 치료적 조성물들 및 생산방법
US8475808B2 (en) 2003-05-23 2013-07-02 Novartis Vaccines And Diagnostics, Inc. Immunogenic reagents from west nile virus
WO2005113775A1 (en) * 2004-05-21 2005-12-01 Simon Fraser University Pproduction of a protein localized to the endoplasmic reticulum protein bodies in a transgenic plant and seed

Also Published As

Publication number Publication date
CA2671934A1 (en) 2008-11-27
EP2099916A2 (en) 2009-09-16
WO2008143713A3 (en) 2009-03-12
US20090069229A1 (en) 2009-03-12
JP2010514698A (ja) 2010-05-06
AR064500A1 (es) 2009-04-08
BRPI0721141A2 (pt) 2014-04-01
US7888069B2 (en) 2011-02-15
WO2008143713A2 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
CN101123871B (zh) 来源于转基因植物细胞的稳定免疫预防性和治疗性组合物及其制备方法
KR101541330B1 (ko) 식물에서 생산된 헤마글루티닌을 포함하는 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
CN102165062B (zh) 新的流感病毒免疫表位
KR101963792B1 (ko) 식물에서 광견병 바이러스 유사 입자 생성
US7888069B2 (en) Plant-made west nile virus (WNV) vaccines, vectors and plant codon optimized sequences
CN101065145B (zh) 嵌合g蛋白基狂犬疫苗
KR20100120157A (ko) 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
KR20110034650A (ko) 헤마글루티닌을 포함하는 인플루엔자 바이러스-유사 입자(ｖｌｐｓ)
EP2486791A2 (en) Highly pathogenic avian influenza virus protein vaccine derived from transgenic plants, and method for preparing same
KR20060035596A (ko) 외래유전자도입 식물로부터 유래된 면역보호성 조성물을제조하기 위한 벡터와 세포
CN102906266A (zh) 登革病毒通用序列及其使用方法
US20100009449A1 (en) Preparation of Vaccine Master Cell Lines Using Recombinant Plant Suspension Cultures
JP2023539356A (ja) 改変コロナウイルス構造タンパク質
Ogrina et al. Bacterial expression systems based on Tymovirus-like particles for the presentation of vaccine antigens
JP2023526770A (ja) 三量体を形成する新型コロナウイルス（ｃｏｖｉｄ－１９、コロナウイルス感染症２０１９）の組換えスパイクタンパク質および植物における上記組換えスパイクタンパク質の大量生産方法と、これを基盤とするワクチン組成物の製造方法（植物における新型コロナウイルスの三量体スパイクタンパク質の生産方法およびワクチン接種のための使用）
Hoang et al. ELPylated avian flu vaccines from plants: Improvement of expression and development of a new purification strategy
Mbewana Development of Rift Valley fever virus candidate vaccines and reagents produced in Nicotiana benthamiana
JP2025501953A (ja) 植物におけるＥｉｍｅｒｉａの配列の発現およびそのための植物産生ワクチン
van Zyl Development of plant-produced Bluetongue virus vaccines
WO2023049983A1 (en) Cpmv vlps displaying sars-cov-2 epitopes
NZ618885B2 (en) Rabies virus like particle production in plants

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period